Pulse Biosciences stock rises after positive cardiac catheter study data

Investing.com -- Pulse Biosciences (NASDAQ: PLSE) stock rose Friday after the company presented promising late-breaking data from its nPulse Cardiac Catheter System first-in-human feasibility study at the AF Symposium.

The study showed 100% procedural success in evaluable patients at 6 months and 96% success at 12 months for the treatment of atrial fibrillation. The data demonstrated the system's effectiveness in treating 150 patients with rapid procedure times and minimal adverse effects.

Key findings from the study included an average of 16.1 applications per procedure, total procedure times of 65 minutes, and a strong safety profile with only 1.3% of subjects experiencing serious adverse events related to the primary safety endpoint.

"These 6- and 12-month data demonstrate a strong safety profile with highly effective and durable PVI achieved with the nPulse Cardiac Catheter Ablation System, suggesting that this system has the ability to considerably advance the treatment of atrial fibrillation," said Vivek Reddy, Director of Cardiac Arrhythmia Services at the Mount Sinai Fuster Heart Hospital.

The ongoing feasibility study has treated a total of 165 patients across nine investigators in Europe. The company's CEO, Paul LaViolette, described the results as "an important milestone" that validates the system's safety, effectiveness, and speed benefits.

Oppenheimer analyst Suraj Kalia commented on the results: "We consider these FIH results encouraging to say the least, though they will need to be proven out in further studies."

The nPulse technology uses proprietary Nanosecond Pulsed Field Ablation energy, which the company believes could revolutionize atrial fibrillation treatment. Pulse Biosciences plans to begin treating additional patients in Europe and the U.S. as it initiates its pivotal IDE study.

You May Also Be Interested In

• BofA maintains underperform ratings on six BDC stocks
• Real and RE/MAX Holdings receive court approval for merger
• loanDepot receives NYSE non-compliance notice over stock price